List of Nature Research journals

NuProbe Closes $50M in New Fundraising

Retrieved on: 
Thursday, June 2, 2022
Genome Biology, VP, Leadership, NGS, Precision medicine, Infertility, Research, Biotechnology, ISO 9001, Liquid biopsy, IVD, R, Business, List of Nature Research journals, CEO, CE, Capital, Medicine, Hospital, Digital, CE marking, Nucleic Acids Research, Patient, Genetic testing, Technology, AstraZeneca, DNA, China Resources, PCR, Amplicon, Industry, GLOBE, Monroe Dunaway Anderson, Genomics, BDA, Nucleic acid, Nature Communications, ISO, Cancer, Diagnosis, Pharmaceutical industry, Medical imaging, Medical device

"In the past year, NuProbe has made great strides in new technology innovation, product development, and business expansion.

Key Points: 
  • "In the past year, NuProbe has made great strides in new technology innovation, product development, and business expansion.
  • "Panlin Capital is committed to supporting NuProbe and its mission and looks forward to NuProbe's continued progress and success."
  • Since NuProbe's last round of fundraising in 2021, NuProbe has engaged in research collaborations with several multinational companies, as well as clinical collaborations with over 400 hospitals.
  • Simultaneously, our recently published Quantitative Amplicon Sequencing (QASeq) technology delivers best-in-class sensitivity for copy number variations," said David Zhang,Co-Founder of NuProbe Global and CEO of NuProbe USA, a fully owned subsidiary of NuProbe Global.

Mechano-therapeutics Discovery Startup Forcyte Bio Secures New Funding From Y Combinator & Others, Bringing Total to >$5.7 Million, to Develop Drug Pipeline

Retrieved on: 
Wednesday, June 1, 2022
Technology, Research, Other Technology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, UCLA, Fibrosis, Cell, Uterus, Blood, Tumor microenvironment, Facioscapulohumeral muscular dystrophy, Doctor of Philosophy, List of Nature Research journals, CEO, Partnership, CRISPR, Algorithm, Biotechnology, Fibroblast, Pioneer Fund, Y Combinator, Pharmaceutical industry, Fine chemical, Mobile phone

Forcyte Biotechnologies, a tech-enabled drug discovery company targeting diseases of mechanobiology, has secured new funding from Milestone View, Pioneer Fund, Acequia Capital, Y Combinator, Jude Gomila (CEO, Golden), and others.

Key Points: 
  • Forcyte Biotechnologies, a tech-enabled drug discovery company targeting diseases of mechanobiology, has secured new funding from Milestone View, Pioneer Fund, Acequia Capital, Y Combinator, Jude Gomila (CEO, Golden), and others.
  • Including public support, this funding brings Forcytes total raised to $5.7M for their internal mechano-therapeutic pipeline, focusing first on fibrosis.
  • Contractile cell function is critically important all throughout the body, in virtually every cell type, and its dysfunction drives many diseases, says co-founder and CEO Ivan Pushkarsky, PhD.
  • The FLECS Platform was developed at and licensed from UCLA by the co-founders and reported in peer-reviewed journals such as Nature Biomedical Engineering .

EtiraRx's Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials

Retrieved on: 
Thursday, June 2, 2022
Endoplasmic reticulum stress in beta cells, Cell death, CEO, Glioblastoma, ER, Therapeutic index, Patient, DRS, Protein folding, LIPA, Heel, Endoplasmic reticulum, Achilles, Vaccine, Pharmaceutical industry, DALLAS, List of Nature Research journals

DALLAS, June 2, 2022 /PRNewswire/ -- A scientific team, led by the scientific founders of EtiraRx, has identified a small molecule, ERX-41, as a novel oral therapeutic agent that may have utility in treating multiple solid cancers, including triple negative breast cancer, glioblastoma, ovarian and pancreatic cancers. EtiraRx, headquartered in Biolabs Pegasus Park, plans to initiate clinical trials as early as the first quarter of 2023.

Key Points: 
  • EtiraRx, headquartered in Biolabs Pegasus Park, plans to initiate clinical trials as early as the first quarter of 2023.
  • Jung-Mo Ahn, Ganesh Raj and Ratna Vadlamudi, identified that ERX-41 dramatically enhances endoplasmic reticulum (ER) stress in cancer cells.
  • The study set the foundation for clinical trials with patients with therapy-resistant cancers that are vulnerable to enhanced ER stress.
  • Russell Hayward, CEO EtiraRx, said, "ERX-41 has the potential to be a first-in-class oral therapy that kills aggressive therapy-resistant cancers.

Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit

Retrieved on: 
Wednesday, June 1, 2022
Sex, Science, NGS, Data analysis, Esophageal cancer, MPS, Neoplasm, Ageing, Plasma, BMC, Identification, BMC Medicine, CE, Blood, DNA methylation, Nucleic acid thermodynamics, Machine learning, Hepatocellular carcinoma, Cancer, Patient, Methylation, Technology, DNA, Discovery, NASDAQ, Ultrasensitivity, List of Nature Research journals, Medical imaging, Phosphorus, Water Drops on Burning Rocks, Water Drops on Burning Rocks

SHANGHAI, June 1, 2022 /PRNewswire/ --Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") announced that it has received CE marking for its OverC Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxuslebenswelt-523/22, DE/CA20/01-IVD-Luxuslebenswelt-524/22).

Key Points: 
  • SHANGHAI, June 1, 2022 /PRNewswire/ --Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock") announced that it has received CE marking for its OverC Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxuslebenswelt-523/22, DE/CA20/01-IVD-Luxuslebenswelt-524/22).
  • OverC Multi-Cancer Detection Blood Test is a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device for the detection of DNA methylation markers using cfDNA isolated from human peripheral whole blood.
  • The OverC test is based on Burning Rock's self-developed multi-cancer early detection technology ELSA-seq.
  • Since 2016, Burning Rock has been committed to promote innovation-driven development, and implement the strategy for early cancer detection.

Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists

Retrieved on: 
Tuesday, May 31, 2022
AR, CRPC, ICB, Population, 1 Canadian Mechanized Brigade Group Headquarters and Signal Squadron, Renji Hospital, Neoplasm, FGFR1, Breast cancer, Shanghai Jiao Tong University, News, Patient, Environment, Lung cancer, Nature, Headquarters, Editorial, Stomach, Esophageal cancer, Research, Hope, IND, Industry, Prostate cancer, Suzhou Industrial Park, Cancer, BMP, Therapy, HKEX, Discovery, List of Nature Research journals, PDX, B cell, Pancreatic cancer, Growth, Castration, Social conditioning, Process, CEO, Jiaotong University, Pharmaceutical industry, Medical imaging

SUZHOU, China, May 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Nature Cancer, an international authoritative journal in oncology field, publishes the results of preclinical studies of Transcenta's first-in-class Gremlin1 targeting antibody (TST003) in the treatment of castration resistant prostate cancer. This research was conducted in collaboration between Transcenta and the team of Professors Helen He Zhu and Wei-Qiang Gao at Renji Hospital, Shanghai JiaoTong University School of Medicine. Professor John T. Isaacs, an internationally renowned expert in prostate cancer research, wrote an editorial and commented that neutralizing antibodies against Gremlin1 could be a potential treatment for androgen receptor-negative/low prostate cancer.

Key Points: 
  • This research was conducted in collaboration between Transcenta and the team of Professors Helen He Zhu and Wei-Qiang Gao at Renji Hospital, Shanghai JiaoTong University School of Medicine.
  • In this study, researchers from Transcenta and Shanghai Jiao Tong University investigated the therapeutic potential of anti-Gremlin1 for prostate cancer in an aggressive mouse model of CRPC (Pbsn-Cre4; Ptenfl/fl; Trp53fl/fl GEMM) and patient derived xenograft (PDX), using TST003, a humanized Gremlin1-targeting antibody, and a surrogate antibody generated by Transcenta.
  • The study results revealed that Gremlin1 protein can promote lineage plasticity and drive castration resistance in prostate cancer.
  • The publication of the study results in Nature Cancer speaks for its novelty and clinical translational value.

VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint

Retrieved on: 
Wednesday, May 25, 2022
Chinese Academy of Sciences, Junshi, Pharmacokinetics, Social responsibility, SSE, Shanghai Institute of Technology, Genoa Joint Laboratories, Bamlanivimab/etesevimab, Arm, Incidence, Phase, COVID-19, Bamlanivimab, Marketing, Research, GLOBE, Death, Lilly, Autoimmunity, R & D, Wuhan Institute of Virology, Infection, FDA, Physics, Communication, HKEX, Severe acute respiratory syndrome coronavirus 2, Neoplasm, Drug discovery, List of Nature Research journals, Belt, Patient, Microbiology, Ministry, Technology, NMPA, Safety, Transfusion-related acute lung injury, Absorption, Pharmaceutical industry, Medical device, Science, Virology, Chinese, Materia medica, Science, Chemistry

SHANGHAI, China, May 25, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 (JT001) and nirmatrelvir/ritonavir (“PAXLOVID”) in the treatment of patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 (JT001) provided patients with a shorter median time to sustained clinical recovery, achieving statistical superiority.

Key Points: 
  • The NCT05341609 study is a multicenter, single-blind, randomized, controlled Phase III study evaluating the efficacy and safety of VV116 (JT001) in comparison with PAXLOVID in the early treatment of patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 and death.
  • The results of this Phase III study, evaluating VV116 (JT001) as a treatment for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 and death, show that the predetermined primary endpoint has been reached.
  • VV116 is currently in an international, multicenter Phase III trial, and a number of clinical studies for mild, moderate and severe COVID-19 are in progress.
  • In 2021, VV116 was approved in Uzbekistan for the treatment of patients diagnosed with moderate to severe COVID-19.

Planet Financial Group Partners with The Farmlink Project

Retrieved on: 
Thursday, May 19, 2022
Climate change, Food, Environment, Solution, Equal housing lender, List of Nature Research journals, Farmer, National Association of Affordable Housing Lenders, Meal, Carbon, Hunger, LLC, PFG, NMLS, Water

MERIDEN, Conn., May 19, 2022 /PRNewswire/ -- Planet Financial Group, LLC, a family of companies delivering innovative origination, servicing, and asset management solutions, will donate $100,000 to The Farmlink Project. The Farmlink Project is a nonprofit grassroots movement that connects surplus produce to communities in need, reduces carbon emissions and empowers the next generation of young changemakers.

Key Points: 
  • Pledges $100,000 to reduce hunger, offset carbon emissions
    MERIDEN, Conn., May 19, 2022 /PRNewswire/ -- Planet Financial Group, LLC , a family of companies delivering innovative origination, servicing, and asset management solutions, will donate $100,000 to The Farmlink Project .
  • "We support Farmlink because we care deeply about the communities we serve and the environment," said Planet Financial Group CEO and President Michael Dubeck.
  • Planet Financial Group, (PFG) LLC, Meriden, Conn., is a fully integrated family of companies delivering innovative origination, servicing, and asset management solutions.
  • PFG is the parent of Planet Home Lending, LLC and Planet Management Group, LLC,which also does business under the name Planet Renovation Capital.

New Milestone Clinical Study Shows Postbiotic Urolithin A (Mitopure™) Improves Muscle Strength and Exercise Performance in Middle Aged Adults

Retrieved on: 
Tuesday, May 17, 2022
Other Sports, Sports, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Inflammation, Longevity, Buck Institute for Research on Aging, Parallel Walk Test, GRAS, JAMA Network Open, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Food, Doctor of Philosophy, Exercise, IRB, Swiss Federal Institute of Aquatic Science and Technology, Ageing, European Journal of Clinical Nutrition, Invention, Muscle, GameChanger, Eating, List of Nature Research journals, Mitophagy, Swiss Federal Institute of Technology, FDA, Swiss, Partnership, European Journal, Human, EPFL, Urolithin A, Nutrition, Biomarker, Health Canada, Federal Institute for Risk Assessment, Mitochondrion, Pomegranate, MD, CEO, Nature Medicine, Dietary supplement, Technology

This milestone study showed that daily intake of Amazentis proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months.

Key Points: 
  • This milestone study showed that daily intake of Amazentis proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months.
  • Muscle strength in the hamstring skeletal muscle was significantly increased in both 500mg (+12%) and 1,000mg groups (+9.8%).
  • Aging is associated with a decline in mitochondrial function which can lead to reduced exercise capacity, muscle endurance and strength.
  • This study is an important milestone and shows that Urolithin A could be a gamechanger in our field.

Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update

Retrieved on: 
Monday, May 9, 2022
EAP, ASCO, Mutation, Memorial Sloan Kettering Cancer Center, Betta, GLOBE, Toxicity, LGR5, Company, Organoid, Safety, Research, Agreement, Bayer, List of Nature Research journals, Patient, ADCP, Webcast, Association, Program, AGM, Metastasis, Degenerative disease, NRG1, American Association, NSCLC, MD, Lilly, Investor, Colorectal cancer, Income, EGFR, Trial of the century, CRC, Growth, ADCC, Large-cell lung carcinoma, HER2, Cryptocurrency, Pharmaceutical industry, Vaccine, Bank, Meru Networks, Novartis, Incyte

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter that ended March 31, 2022, and provided a business update.

Key Points: 
  • We are also looking forward to sharing clinical updates of Peto and MCLA-129 in the second half of 2022 at medical conferences.
  • Details of the eNRGy trial can be found at www.ClinicalTrials.gov and Merus trial website at www.nrg1.com, or by calling 1-833-NRG-1234.
  • A clinical update is planned for the second half of 2022 at a medical conference.
  • On April 25, 2022, we announced the publication of a preclinical report of Peto in the journal Nature Cancer.

Crown Bioscience: First Clinical Candidate Developed Using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer

Retrieved on: 
Thursday, April 28, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Antibody, Drug discovery, Adult, Wellcome Sanger Institute, Metastasis, Organoid, Life, CEO, Immune-mediated inflammatory diseases, Catalan Institute of Nanotechnology, Royal Netherlands Academy of Arts and Sciences, Patient, Collection, Vall, Cancer, Technology, HUB, Growth, Crown Bioscience International, Achievement, Therapy, PDX, Senior, Multimedia, Wilms' tumor, Regenerative medicine, List of Nature Research journals, List of life sciences, Social, FP7, Colorectal cancer, EU, CRO, Meru Networks, Vaccine, Medical imaging, Pharmaceutical industry

Crown Bioscience and HUB led the design of the experiments which were executed using the high content screening platform from Crown Bioscience using HUB Organoids.

Key Points: 
  • Crown Bioscience and HUB led the design of the experiments which were executed using the high content screening platform from Crown Bioscience using HUB Organoids.
  • Follow up in vivo studies in matched patient-derived xenograft (PDX) models were also performed by Crown Bioscience.
  • This groundbreaking work demonstrates the power and potential of HUB Organoid Technology, commented Rob Vries PhD, CEO at HUB.
  • HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoid.